At the news
? MIXEDIMPACT 6/10 8-K filed Feb 24, 2026 at 16:12 ET
Evolent Health reported a significant year-over-year decline in revenue and net loss for 2025, driven by goodwill and other impairments. However, the company guided for approximately 30% revenue growth in 2026, citing strong customer retention and a robust pipeline. Adjusted EBITDA remained stable at $151 million, but 2026 guidance projects a decline to $110-$140 million due to near-term investments and membership changes.
- 2025 revenue declined 26.5% YoY to $1.876 billion, primarily due to a $398 million goodwill impairment.
- Adjusted EBITDA was $151.2 million in 2025, flat year-over-year, with a stable 8.1% margin.
- The company guided for 2026 revenue of $2.4-$2.6 billion (approx. 30% growth) and Adjusted EBITDA of $110-$140 million.
- Management cited $900 million in new Performance Suite revenue for 2026 but expects near-term margin pressure.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access